T. Rowe Price Investment Management, Inc.

Position in RAPP — Rapport Therapeutics, Inc.

CIK 1897612 BALTIMORE, MD

Position in RAPP

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$16,384,644

-$3,033,930 QoQ

Shares Held

393,200

-36.6% QoQ

Ownership

0.820%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#23

of 159 holders

Holding Since

Jun 2024

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,305,680,119 across 52 Biotechnology names. RAPP ranks #44 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$16,384,644	393,200	-36.6%	Shares	Sole	2026-08-14
2026-03-31	$19,418,574	620,600	+164.3%	Shares	Sole	2026-05-15
2025-12-31	$7,122,891	234,769	-66.8%	Shares	Sole	2026-02-17
2025-09-30	$21,012,987	707,508	+15.3%	Shares	Sole	2025-11-14
2025-06-30	$6,979,122	613,819	-60.4%	Shares	Sole	2025-08-14
2025-03-31	$15,565,807	1,551,925	-5.2%	Shares	Sole	2025-05-14
2024-12-31	$29,039,155	1,636,931	-5.2%	Shares	Sole	2025-02-14
2024-09-30	$35,371,233	1,727,111	+12.5%	Shares	Sole	2024-11-14
2024-06-30	$35,707,612	1,535,151	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.